{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:33:28Z","timestamp":1790202808535,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Karuna Therapeutics"},{"name":"Bristol Myers Squibb company"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The FDA approval in 2024 of the M1\/M4 muscarinic receptor agonist xanomeline and trospium chloride (formerly known as KarXT) introduces a novel alternative to dopamine-receptor antagonism or partial agonism for schizophrenia treatment. All prior approved treatments rely on direct D2-receptor antagonism or partial agonism, limiting patient experiences to this mechanism. To explore this shift, we conducted a qualitative study examining patient experiences with a muscarinic receptor agonist. A companion report addresses perceived symptom changes; this report focuses on changes in quality of life (QoL) and medication satisfaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Methods<\/jats:title>\n                    <jats:p>A qualitative substudy was embedded in a larger 52-week open-label trial of xanomeline\/trospium monotherapy in stable schizophrenia outpatients transitioned from standard antipsychotics. It included semi-structured interviews at 6\u00a0weeks (n\u2009=\u200970) and 6\u00a0months (n\u2009=\u200947) after initiating treatment. Narratives regarding change in QoL attributed to xanomeline\/trospium and medication satisfaction were coded and categorized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>Before starting xanomeline\/trospium, most participants reported QoL challenges across the following domains: physical (95.7%), social (85.7%), and role (80.0%) functioning, and emotional well-being (74.3%). For the two most common issues in each domain, the percentage of participants who improved by 6\u00a0weeks ranged from 44.8% to 83.3%, increasing to 68.0% to 95.2% by 6\u00a0months after xanomeline\/trospium initiation. Few participants worsened in any of these domains. Participants rated their satisfaction with xanomeline\/trospium highly (mean\u2009=\u20098.1 out of 10 at both assessments) and 93.2% would recommend it to a friend.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Xanomeline\/trospium treatment was associated with meaningful improvements across QoL domains that participants had previously identified as challenging, and most participants reported high satisfaction with the medication. These findings should be interpreted cautiously given the open-label design, absence of a comparator group, and potential selection and attrition biases. Within these constraints, the results provide exploratory, participant-centered insights into treatment experience and suggest that muscarinic agonists may influence both symptomatic and functional aspects of schizophrenia, warranting further controlled investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schizbullopen\/sgag003","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:41:49Z","timestamp":1771418509000},"source":"Crossref","is-referenced-by-count":2,"title":["A Qualitative Investigation of the Experience of Taking Xanomeline and Trospium Chloride for Schizophrenia, Part 2: Perceived Changes in Subjective Quality of Life and Medication Satisfaction"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5583-5871","authenticated-orcid":false,"given":"Peter","family":"Weiden","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Health, Renaissance School of Medicine at Stony Brook University , Stony Brook, NY 11794 ,","place":["USA"]},{"name":"Bristol Myers Squibb , Princeton, NJ 08543 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Saucier","sequence":"additional","affiliation":[{"name":"IQVIA Quality Metric, Inc. Johnston , Rhode Island 02919"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April M","family":"Foster","sequence":"additional","affiliation":[{"name":"IQVIA Quality Metric, Inc. Johnston , Rhode Island 02919"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Claxton","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ 08543 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Chatuvedi","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ 08543 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Sauder","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ 08543 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"LaGasse","sequence":"additional","affiliation":[{"name":"IQVIA Quality Metric, Inc. Johnston , Rhode Island 02919"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sloan","family":"Rucker","sequence":"additional","affiliation":[{"name":"IQVIA Quality Metric, Inc. Johnston , Rhode Island 02919"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Jackson","sequence":"additional","affiliation":[{"name":"IQVIA Quality Metric, Inc. Johnston , Rhode Island 02919"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0288-309X","authenticated-orcid":false,"given":"Stephen R","family":"Marder","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Biobehavioral Sciences, University of California , Los Angeles, CA 90095 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sonnenberg","sequence":"additional","affiliation":[{"name":"Uptown Research Institute , Chicago, IL 60640 ,","place":["USA"]},{"name":"Department of Psychiatry and Biobehavioral Sciences, Northwestern University Feinberg School of Medicine , Chicago, Illinois 60611 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inder","family":"Kaul","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ 08543 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P","family":"Horan","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ 08543 ,","place":["USA"]},{"name":"Department of Psychiatry and Biobehavioral Sciences, University of California , Los Angeles, CA 90095 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2026052103070605600_ref1","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia\u2014data, with critical appraisal, from the global burden of disease (GBD) 2019","volume":"28","author":"Solmi","year":"2023","journal-title":"Mol Psychiatry"},{"key":"2026052103070605600_ref2"},{"key":"2026052103070605600_ref3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/wps.20385","article-title":"The current conceptualization of negative symptoms in schizophrenia","volume":"16","author":"Marder","year":"2017","journal-title":"World Psychiatry Feb"},{"key":"2026052103070605600_ref4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/wps.20624","article-title":"Nonsocial and social cognition in schizophrenia: current evidence and future directions","volume":"18","author":"Green","year":"2019","journal-title":"World Psychiatry Jun"},{"key":"2026052103070605600_ref5","doi-asserted-by":"crossref","first-page":"112681","DOI":"10.1016\/j.psychres.2019.112681","article-title":"Depression predicts self assessment of social function in both patients with schizophrenia and healthy people","volume":"284","author":"Oliveri","year":"2020","journal-title":"Psychiatry Res Feb"},{"key":"2026052103070605600_ref6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0920-9964(99)00151-6","article-title":"Quality of life in schizophrenia: contributions of anxiety and depression","volume":"51","author":"Huppert","year":"2001","journal-title":"Schizophr Res"},{"key":"2026052103070605600_ref7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.wpsyc.2012.05.004","article-title":"Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status","volume":"11","author":"Harvey","year":"2012","journal-title":"World Psychiatry Jun"},{"key":"2026052103070605600_ref8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jagp.2023.10.014","article-title":"Computerized cognitive and skills training in older people with mild cognitive impairment: using ecological momentary assessment to index treatment-related changes in real-world performance of technology-dependent functional tasks","volume":"32","author":"Dowell-Esquivel","year":"2024","journal-title":"Am J Geriatr Psychiatry Apr"},{"key":"2026052103070605600_ref9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2975\/30.3.2007.219.222","article-title":"Quality of life for persons living with schizophrenia: more than just symptoms","volume":"30","author":"Eack","year":"2007","journal-title":"Psychiatr Rehabil J"},{"key":"2026052103070605600_ref10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fnins.2013.00062","article-title":"Prefrontal dopamine and behavioral flexibility: shifting from an \u201cinverted-U\u201d toward a family of functions","volume":"7","author":"Floresco","year":"2013","journal-title":"Front Neurosci"},{"key":"2026052103070605600_ref11","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/brain\/aww050","article-title":"Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology","volume":"139","author":"Salamone","year":"2016","journal-title":"Brain"},{"key":"2026052103070605600_ref12","first-page":"368","article-title":"Subcortical dopamine dysfunction in schizophrenia: insights from cognitive and imaging studies","volume":"118","author":"Barch","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"key":"2026052103070605600_ref13","first-page":"107","article-title":"Integrating reward and cognitive dysfunction in schizophrenia: a theoretical framework and review","volume":"212","author":"Reddy","year":"2019","journal-title":"Schizophr Res"},{"key":"2026052103070605600_ref14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"2026052103070605600_ref15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0924-977X(01)00128-6","article-title":"The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study","volume":"12","author":"Ritsner","year":"2002","journal-title":"Eur Neuropsychopharmacol Feb"},{"key":"2026052103070605600_ref16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/19585969.2025.2463443","article-title":"Impact of perceived side-effects of psychotropic treatments on quality of life in patients with severe mental illness","volume":"27","author":"Korchia","year":"2025","journal-title":"Dialogues Clin Neurosci"},{"key":"2026052103070605600_ref17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.psc.2009.08.003","article-title":"Management of schizophrenia with obesity, metabolic, and endocrinological disorders","volume":"32","author":"Monteleone","year":"2009","journal-title":"Psychiatr Clin North Am Dec"},{"key":"2026052103070605600_ref18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/PPA.S124658","article-title":"Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness","volume":"11","author":"Velligan","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"2026052103070605600_ref19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11126-019-09633-4","article-title":"Quality of life in schizophrenia: a meta-analysis of comparative studies","volume":"90","author":"Dong","year":"2019","journal-title":"Psychiatr Q"},{"key":"2026052103070605600_ref20","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/schbul\/sbl071","article-title":"Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis","volume":"33","author":"Eack","year":"2007","journal-title":"Schizophr Bull"},{"key":"2026052103070605600_ref21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1600-0447.2005.00717.x","article-title":"Determinants of quality of life in people with severe mental illness","volume":"429","author":"Hansson","year":"2006","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"2026052103070605600_ref22","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13111577","article-title":"A systematic review on the effectiveness of antipsychotic drugs on the quality of life of patients with schizophrenia","volume":"13","author":"Sampogna","year":"2023","journal-title":"Brain Sci"},{"key":"2026052103070605600_ref23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12888-024-05929-3","article-title":"Exploring the interplay of psychiatric symptoms, antipsychotic medications, side effects, employment status, and quality of life in chronic schizophrenia","volume":"24","author":"Zhou","year":"2024","journal-title":"BMC Psychiatry"},{"key":"2026052103070605600_ref24","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N Engl J Med"},{"key":"2026052103070605600_ref25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"key":"2026052103070605600_ref26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41537-022-00320-1","article-title":"Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia","volume":"8","author":"Correll","year":"2022","journal-title":"Schizophrenia (Heidelb)"},{"key":"2026052103070605600_ref27","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00213-023-06362-2","article-title":"Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results","volume":"240","author":"Breier","year":"2023","journal-title":"Psychopharmacology"},{"key":"2026052103070605600_ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"2026052103070605600_ref29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia","volume":"179","author":"Paul","year":"2022","journal-title":"Am J Psychiatry"},{"key":"2026052103070605600_ref30","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.tips.2022.09.006","article-title":"Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic","volume":"43","author":"Yohn","year":"2022","journal-title":"Trends Pharmacol Sci Dec"},{"key":"2026052103070605600_ref31","doi-asserted-by":"crossref","first-page":"1421554","DOI":"10.3389\/fpsyt.2024.1421554","article-title":"The potential of muscarinic M(1) and M(4) receptor activators for the treatment of cognitive impairment associated with schizophrenia","volume":"15","author":"Yohn","year":"2024","journal-title":"Front Psychiatry"},{"key":"2026052103070605600_ref32","article-title":"A qualitative investigation of the experience of taking Xanomeline and Trospium chloride for schizophrenia, part 1: perceived impact on symptoms","author":"Horan","journal-title":"Schizophr Bull Open"},{"key":"2026052103070605600_ref33","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20241186","article-title":"Long-term safety and efficacy of Xanomeline and Trospium chloride in schizophrenia: a 52-week open-label extension trial","volume":"183","author":"Kaul","year":"2026","journal-title":"Am J Psychiatry"},{"key":"2026052103070605600_ref34","first-page":"140","article-title":"World Health Organization quality-of-life scale (WHOQOL-BREF): analyses of their item response theory properties based on the graded responses model","volume":"5","author":"Vahedi","year":"2010","journal-title":"Iran J Psychiatry Fall"},{"key":"2026052103070605600_ref35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care Jun"},{"key":"2026052103070605600_ref36","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/01.mlr.0000254567.79743.e2","article-title":"Evaluation of item candidates: the PROMIS qualitative item review","volume":"45","author":"DeWalt","year":"2007","journal-title":"Med Care May"},{"key":"2026052103070605600_ref37","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0885-3924(94)90129-5","article-title":"Quality of life: concepts and definition","volume":"9","author":"Cella","year":"1994","journal-title":"J Pain Symptom Manage Apr"},{"key":"2026052103070605600_ref38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/0963721410377599","article-title":"Emotion in schizophrenia: where feeling meets thinking","volume":"19","author":"Kring","year":"2010","journal-title":"Curr Dir Psychol Sci"},{"key":"2026052103070605600_ref39","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.psychres.2018.12.060","article-title":"The impact of internalized stigma on the well-being of people with schizophrenia","volume":"271","author":"Morgades-Bamba","year":"2019","journal-title":"Psychiatry Res"},{"key":"2026052103070605600_ref40","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.psc.2017.08.005","article-title":"The effect of cognitive Behavioral interventions on depression and anxiety symptoms in patients with schizophrenia Spectrum disorders: a systematic review","volume":"40","author":"Opoka","year":"2017","journal-title":"Psychiatr Clin North Am Dec"},{"key":"2026052103070605600_ref41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/schbul\/sbn177","article-title":"Psychosocial treatments to promote functional recovery in schizophrenia","volume":"35","author":"Kern","year":"2009","journal-title":"Schizophr Bull"},{"key":"2026052103070605600_ref42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1017\/S1092852915000917","article-title":"Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study","volume":"21","author":"Correll","year":"2016","journal-title":"CNS Spectr"},{"key":"2026052103070605600_ref43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41537-021-00190-z","article-title":"Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study","volume":"7","author":"Correll","year":"2021","journal-title":"NPJ Schizophr"}],"container-title":["Schizophrenia Bulletin Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizbullopen\/advance-article-pdf\/doi\/10.1093\/schizbullopen\/sgag003\/66989303\/sgag003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article-pdf\/7\/1\/sgag003\/66989303\/sgag003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article-pdf\/7\/1\/sgag003\/66989303\/sgag003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T07:07:15Z","timestamp":1779347235000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizbullopen\/article\/doi\/10.1093\/schizbullopen\/sgag003\/8490301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,22]]}},"URL":"https:\/\/doi.org\/10.1093\/schizbullopen\/sgag003","relation":{},"ISSN":["2632-7899"],"issn-type":[{"value":"2632-7899","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"sgag003"}}